Ophthalmology
Volume 111, Issue 10 , Pages 1847-1852, October 2004

Ophtec iris reconstruction lens United States clinical trial phase I☆

Presented in part at: American Academy of Ophthalomology Annual Meeting, November, 2003; Anaheim, California.

  • Marianne O. Price, PhD

      Affiliations

    • Cornea Research Foundation of America, Indianapolis, Indiana, USA
    • ,
  • Francis W. Price Jr, MD

      Affiliations

    • Price Vision Group, Indianapolis, Indiana, USA
    • Corresponding Author InformationCorrespondence to Francis W. Price, Jr, MD, Price Vision Group, 9002 North Meridian Street, Suite 100, Indianapolis, IN 46260, USA, Attn: Sherry Levy.
    • ,
  • David F. Chang, MD

      Affiliations

    • University of California, San Francisco, San Francisco, California, USA
    • ,
  • Kathy Kelley, OD

      Affiliations

    • Price Vision Group, Indianapolis, Indiana, USA
    • ,
  • Michael D. Olson, OD, PhD

      Affiliations

    • Jules Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    • ,
  • Kevin M. Miller, MD

      Affiliations

    • Jules Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA

Received 14 January 2004; accepted 19 April 2004. published online 16 September 2004.

Abstract 

Purpose

To determine the safety and efficacy of the Ophtec model 311 iris reconstruction lens for treatment of visual disturbances, such as glare or photophobia, related to partial or total absence of the human iris.

Design

Phase I multicenter, nonrandomized, investigational device study.

Participants

Ten iris reconstruction lenses were placed in 10 subjects at 6 sites.

Methods

Iris reconstruction lenses were placed in 9 patients who had lost all or part of their iris from trauma and in 1 patient who lacked iris pigmentation due to congenital albinism. Patients were examined preoperatively, intraoperatively, and postoperatively at day 1; week 1; and months 1, 3, 6, and 12.

Main outcome measures

Efficacy measures were uncorrected visual acuity (UCVA), glare, starbursts, and photophobia. Safety measures were best-corrected visual acuity (VA), surgical complications, and adverse events.

Results

Uncorrected VA improved in all eyes after implantation of the iris reconstruction lens. Best-corrected VA did not change significantly (P = 0.24). Postoperative photophobia was reduced in all 9 eyes that experienced moderate to severe preoperative photophobia. Likewise, postoperative glare was reduced in all 6 eyes with moderate to severe preoperative glare. There were no surgical complications. Adverse events included 2 cases of iritis and 1 case of macular edema.

Conclusions

Preliminary results suggest that the Ophtec model 311 iris reconstruction lens can improve UCVA and reduce glare and photophobia in patients with partial or total absence of the iris or iris pigmentation.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Manuscript no. 240039.The authors have no financial interests related to this article or devices mentioned therein.The study was sponsored by Ophtec USA, Inc., Boca Raton, Florida.

PII: S0161-6420(04)00819-X

doi:10.1016/j.ophtha.2004.04.023

Ophthalmology
Volume 111, Issue 10 , Pages 1847-1852, October 2004

Article Tools

* Image Usage & Resolution